News

November 30, 2018November 30, 2018

European Union Expands Kalydeco’s Approval to Certain CF Patients Ages 1-2

cystic fibrosis, News

Kalydeco (ivacaftor) by Vertex Pharmaceuticals has been approved in the European Union for children ages 1-2 with cystic fibrosis (CF) who carry at least one of nine mutations in the CFTR gene — G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R — ... Read more

November 29, 2018November 29, 2018

Triple Combo with VX-659 Improves Lung Function in CF Patients with F508del Mutation, Phase 3 Trials Show

cystic fibrosis, News

Treatment with a triple combination — the new CFTR corrector VX-659, together with tezacaftor and Kalydeco (ivacaftor) — significantly improved lung function and was well-tolerated by cystic fibrosis (CF) patients, ages 12 ... Read more

November 28, 2018November 28, 2018

Study Reveals How Cystic Fibrosis Affects Young Women’s Sexual Health

cystic fibrosis, News

Girls with cystic fibrosis (CF) reach puberty six to eight months later than healthy girls, about 16 percent of young females with CF encounter problems during sex, and 78 percent ... Read more

November 27, 2018November 27, 2018

GEn1E to Explore MUC1-ED to Prevent P. Aeruginosa Infections in CF

cystic fibrosis, News

GEn1E Lifesciences has added to its development pipeline an investigational non-antibiotic, antibacterial agent for treatment of Pseudomonas aeruginosa infections in people with cystic fibrosis (CF). The company established an exclusive option ... Read more

November 26, 2018November 26, 2018

P. aeruginosa Toxin May Be Reason for Single Strains Found in CF Infections, Study Reports

cystic fibrosis, News

A protein toxin called Tse7 is used by Pseudomonas aeruginosa to kill neighboring bacteria, and may help explain why lung infections in cystic fibrosis patients are often dominated by a ... Read more

November 20, 2018November 20, 2018

New Tissue-specific Delivery of CRISPR/Cas9 Aided by Moth Virus and Magnets, Study Shows

cystic fibrosis, News

Rice University researchers are using a virus that infects moths and magnetic nanoparticles to develop a new vehicle for the delivery of CRISPR/Cas9, a genome-editing tool, with high efficiency and ... Read more

November 19, 2018November 19, 2018

Orkambi Closer to Being Approved in Europe to Treat Children Ages 2-5 With Cystic Fibrosis

cystic fibrosis, News

The European Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Orkambi (lumacaftor/ivacaftor) as a treatment for children ages 2-5 with cystic fibrosis (CF) due to F508del mutations, ... Read more

November 16, 2018November 16, 2018

New Test of Mucus Properties May Help with Coughing and Airway Clearance in CF

cystic fibrosis, News

A new test was able to assess various properties of the mucus that accumulates in the lungs of people with cystic fibrosis and other pulmonary diseases, and may help ... Read more

November 15, 2018November 15, 2018

Ultrasound Predicts Advanced Liver Disease in CF Patients, According to Clinical Trial Data

cystic fibrosis, News

Ultrasound may predict liver disease in young cystic fibrosis (CF) patients, according to the results of a clinical trial. Researchers compared liver patterns from young CF patients, and found ... Read more

November 14, 2018November 14, 2018

Avycaz May Be Effective for Multidrug-resistant P. aeruginosa Infections in CF Patients, Study Suggests

cystic fibrosis, News

Antibacterial Avycaz (ceftazidime-avibactam) showed significant in vitro efficacy against multidrug-resistant Pseudomonas aeruginosa collected from the sputum of cystic fibrosis (CF) patients, according to a recent study. The study, “Multidrug-resistant Pseudomonas aeruginosa from ... Read more

Pin It on Pinterest